EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tranexamic acid in high-risk shoulder arthroplasty patients: safety across thromboembolic, cardiac, renal, and neurologic risk profiles

Tarishi Parmar, Akin Adio, Asim Handy, Mohammad Daher, Alec Kellish, Adam Khan, Joseph Abboud

Archives of Orthopaedic and Trauma Surgery · 03.07.2026 · 146 (1)

DOI: 10.1007/s00402-026-06406-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Orthopaedic and Trauma Surgery, online erschienen am 03.07.2026. Verfasst von Tarishi Parmar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, USA. txp539@students.jefferson.edu. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Shoulder, Tranexamic Acid, Antifibrinolytic Agents, Postoperative Complications. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tranexamic acid (TXA) effectively reduces blood loss and transfusion requirements in shoulder arthroplasty. However, concerns regarding thromboembolic, neurologic, cardiac, and renal complications have limited its use in medically high-risk patients. This study evaluated temporal trends and the safety of TXA in high-risk patients undergoing total shoulder arthroplasty (TSA).

Methods

A retrospective cohort study was conducted using TriNetX, identifying patients who underwent shoulder arthroplasty (2012–2025). Patients were stratified by preexisting high-risk conditions, including prior thromboembolism, renal failure, atrial fibrillation, seizure disorders, and visual disturbances. Within each subgroup, patients receiving TXA were propensity score–matched to those who did not. Perioperative TXA utilization trends were assessed. Ninety-day postoperative outcomes were compared, including transfusion requirements, thromboembolic events, cardiac complications, renal failure, neurologic events, infections, readmissions, emergency department visits, and mortality. Outcomes were reported as odds ratios (ORs) with 95% confidence intervals (CIs).

Results

Reported perioperative TXA use began in 2012 and increased through 2025, with over 70% of patients in both standard- and high-risk cohorts receiving TXA. TXA use was associated with significantly lower transfusion rates (OR range 0.53–0.62) and readmissions (OR range 0.63–0.75) across all high-risk cohorts (all p ≤ 0.01). TXA use was not associated with increased risk of deep vein thrombosis, pulmonary embolism, stroke, or postoperative seizures in any subgroup. Notably, TXA demonstrated a protective association against myocardial infarction, cardiac ischemia, acute renal failure, and mortality in select high-risk populations. No increase in infection-related complications was observed.

Conclusions

In patients undergoing shoulder arthroplasty, TXA use was safe across multiple high-risk medical populations and was consistently associated with lower transfusion and readmission rates, with reduced mortality in select cohorts. These findings support the broader use of TXA for blood conservation in shoulder arthroplasty, even among patients with traditionally high-risk comorbidities, while underscoring the need for future prospective, shoulder-specific safety studies. Level of evidence III, Retrospective Cohort Study

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthroplasty, Replacement, ShoulderTranexamic AcidAntifibrinolytic AgentsPostoperative ComplicationsBlood Loss, SurgicalHumansRetrospective StudiesFemaleMaleAgedThromboembolismMiddle AgedBlood TransfusionRisk FactorsHeart Diseases

Stichwörter der Autor:innen

Blood lossHigh-risk patientsPerioperative safetyShoulder arthroplastyTranexamic acidTransfusion

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, USA. txp539@students.jefferson.edu.
  • Department of Shoulder and Elbow Surgery, Rothman Orthopaedics, Philadelphia, USA. txp539@students.jefferson.edu.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
  • University of Pennsylvania, Philadelphia, USA.
  • Department of Shoulder and Elbow Surgery, Rothman Orthopaedics, Philadelphia, USA.
  • Department of Orthopaedic Surgery, Southern California Permanente Medical Group, Kaiser Permanente, Panorama City, USA.

Zitieren

APA

Parmar, T., Adio, A., Handy, A., Daher, M., Kellish, A., Khan, A., & Abboud, J. (2026). Tranexamic acid in high-risk shoulder arthroplasty patients: safety across thromboembolic, cardiac, renal, and neurologic risk profiles. Archives of Orthopaedic and Trauma Surgery, 146(1). https://doi.org/10.1007/s00402-026-06406-0

Vancouver

Parmar T, Adio A, Handy A, Daher M, Kellish A, Khan A, et al. Tranexamic acid in high-risk shoulder arthroplasty patients: safety across thromboembolic, cardiac, renal, and neurologic risk profiles. Archives of Orthopaedic and Trauma Surgery. 2026;146(1). doi:10.1007/s00402-026-06406-0

BibTeX
@article{Parmar2026,
  author = {Parmar, Tarishi and Adio, Akin and Handy, Asim and Daher, Mohammad and Kellish, Alec and Khan, Adam and Abboud, Joseph},
  title = {Tranexamic acid in high-risk shoulder arthroplasty patients: safety across thromboembolic, cardiac, renal, and neurologic risk profiles},
  journal = {Archives of Orthopaedic and Trauma Surgery},
  year = {2026},
  volume = {146},
  number = {1},
  doi = {10.1007/s00402-026-06406-0}
}
Kostenlos starten →